{
    "clinical_study": {
        "@rank": "57142", 
        "acronym": "Botox", 
        "arm_group": [
            {
                "arm_group_label": "Botox", 
                "arm_group_type": "Experimental", 
                "description": "See Botox intervention description"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "See Placebo Intervention Description"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if botulinum toxin type A (Botox) injections, at\n      the time of surgery for pilon fractures, will improve ankle range-of-motion and\n      functionality."
        }, 
        "brief_title": "The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures", 
        "completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Equinus Contracture", 
        "condition_browse": {
            "mesh_term": [
                "Clubfoot", 
                "Equinus Deformity", 
                "Contracture"
            ]
        }, 
        "detailed_description": {
            "textblock": "To determine if the use of Botulinum toxin A intramuscular injections of the gastrocsoleus\n      complex in patients with operatively treated tibial plafond fractures will result in:\n\n        1. increased ankle dorsiflexion when compared to controls\n\n        2. increased ankle functionality as measured by the FAAM, and quality of life as measured\n           by the SF-36, when compared to controls\n\n        3. a higher proportion of patients achieving at least 10 degrees of dorsiflexion when\n           compared to controls"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients 18 and older with a tibial plafond fracture to be treated by a staged\n             protocol involving primary external fixation and definitive fixation within 3 weeks\n             from the injury.\n\n        (Non-definitive, interval procedures such as repeat irrigation and debridement and fibular\n        fixation are allowed.)\n\n        Exclusion Criteria:\n\n          -  Younger than 18 years of age\n\n          -  Significant traumatic brain injury or cognitive disability that would interfere with\n             post-operative rehabilitation and study questionnaires\n\n          -  Nerve, vascular, or tendon injury of the lower leg: injury to the tibial or peroneal\n             motor nerves, injury to the posterior tibial artery requiring repair, or laceration\n             of tendons that are involved in plantar flexion or dorsiflexion of the ankle which\n             require repair\n\n          -  History of prior lower extremity fracture to the tibia or ankle of the affected limb.\n\n          -  Incarcerated patients.\n\n          -  Patients unable or unwilling to return for follow-up examination.\n\n          -  Pregnant or lactating patients.\n\n          -  History of disease affecting the neuromuscular junction (ex: myasthenia gravis).\n\n          -  Use of aminoglycoside antibiotics at the time of definitive fixation.\n\n          -  Ipsilateral foot injury that will impair dorsiflexion exercises: Lisfranc injuries,\n             fractures or dislocations of the talus, calcaneus, navicular, cuboid, cuneiforms, or\n             metatarsals (phalanx fractures or dislocations will not be excluded).\n\n          -  Patients receiving Botulinum Toxin A for other reasons.\n\n          -  Patients with a known hypersensitivity to Botulinum toxin A.\n\n          -  Gustilo Anderson type III B and C.\n\n          -  Patients with a weight greater than 115 kg - to ensure proper injection locations"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02051933", 
            "org_study_id": "03-12-19B"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).\n45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U", 
                "intervention_name": "Botox", 
                "intervention_type": "Drug", 
                "other_name": "Botulinum toxin A"
            }, 
            {
                "arm_group_label": "Botox", 
                "description": "At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of  0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).\n45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "0.9% sodium chloride solution for injection"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "pilon", 
            "tibial plafond", 
            "botox", 
            "ankle dorsiflexion", 
            "ankle functionality", 
            "ankle range of motion"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "email": "madhav.karunakar@carolinashealthcare.org", 
                "last_name": "Madhav A Karunakar, M.D.", 
                "phone": "704-355-4638"
            }, 
            "facility": {
                "address": {
                    "city": "Charlotte", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "28204"
                }, 
                "name": "Carolinas Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Madhav A Karunakar, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Michael Bosse, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "James Kellam, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Stephen Sims, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nikkole Haines, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Ruffolo, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bruce Cohen, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kent Ellington, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Joseph Hsu, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rachel Seymour, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Plafond (Pilon) Fractures: A Pilot Study", 
        "overall_contact": {
            "email": "madhav.karunakar@carolinashealthcare.org", 
            "last_name": "Madhav A Karunakar, M.D.", 
            "phone": "704-355-4638"
        }, 
        "overall_official": {
            "affiliation": "Carolinas Healthcare System", 
            "last_name": "Madhav A Karunakar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome variable will be ankle dorsiflexion of the injured extremity as measured by equinometer device using a constant torque (10Nm) with knee fully extended and at 90 degrees of flexion.", 
            "measure": "Change in Ankle Dorsiflexion of Injured Extremity", 
            "safety_issue": "No", 
            "time_frame": "6 and 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02051933"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Carolinas Healthcare System", 
            "investigator_full_name": "Madhav Karunakar", 
            "investigator_title": "Orthopaedic Traumatologist, Department of Orthopaedic Surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "SF-36 will be used to measure health-related quality of life.", 
                "measure": "Change in Health Related Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "6 month and 12 month follow-up visits"
            }, 
            {
                "description": "Overall study limb, as well as ankle specific, pain intensity will be measured using the 0-10 visual analog scale used in the Brief Pain Inventory", 
                "measure": "Change in Pain", 
                "safety_issue": "No", 
                "time_frame": "6 month and 12 month follow-up visits"
            }, 
            {
                "description": "The FAAM will be obtained to assess the functional status of the affected ankle.", 
                "measure": "Change in functional status of the Ankle", 
                "safety_issue": "No", 
                "time_frame": "6 month and 12 month follow-up visits"
            }
        ], 
        "source": "Carolinas Healthcare System", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Carolinas Healthcare System", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}